Abstract
Purpose
Gallbladder and pancreas share common embryological origin, and malignancies of these organs may share common tumor antigens. CA 242 is a tumor marker for pancreatic cancer, but has not been studied in gallbladder cancer (GBC). We measured serum CA 242 levels in patients with GBC and compared it with those in patients with gallstones (GS) and healthy volunteers.
Methods
We enrolled consecutive patients with GBC (cases), GS (disease controls), and healthy volunteers (healthy controls). Serum CA 242, CEA, and CA 19–9 levels were measured using ELISA. Receiver operator curve was plotted for all the three markers.
Results
We studied 117 patients with GBC, 58 with GS, and 10 healthy volunteers. Among patients with GBC, 81 (69%) also had GB calculi. Patients with GBC more often had elevated CA 242 levels (64%) compared to those with GS (17%; p < 0.001) and healthy controls (0%; p < 0.001). The median levels of CA 242 was higher in the GBC group (59 [199] U/ml) compared to the GS group (10 [13] U/ml; p < 0.001) and the control group (3 [14.5] U/ml; p < 0.001). The sensitivity, specificity, positive predictive value (PPV), and negative predictive values of CA 242 for diagnosis of GBC were 64%, 83%, 88%, and 53%, respectively. At a cutoff of 45 U/ml, the specificity and PPV increased to 100%. CA 242 had higher AOC (0.759) compared to CEA (0.528) and CA 19–9 (0.430).
Conclusions
CA 242 is a promising tumor marker for GBC and performs better than CEA and CA 19-9.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Zatonski WA, Lowenfields AB, Boyle P, et al. Epidemiologic aspects of gallbladder cancer: a case controlled study of the Search Programme of the International Agency for Research on Cancer. J Natl Cancer Inst. 1997;89:1132–8.
Parkin DM, Muir CS, Whelan SL, GAo YT, Ferlay J, Powells J (eds). (1992) Cancer incidence in 5 continents. Vol VI. IARC Scientific publications NO 120. Lyon: IARC
ICMR National Cancer Registry Program, Biennial Report 1988–89. An epidemiological study. New Delhi: ICMR; 1992. p. 14–5.
Kapoor VK, McMichael AJ. Gallbladder cancer: an Indian disease. Natl Med J India. 2003;16:209–13.
Rothlin MA, Joller H, Largiader F. CA 242 is a new tumor marker for pancreatic cancer. Cancer. 1993;71:701–7.
Haglund C, Lundin J, Kuusela P, Roberts PJ. CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19–9, CA 50 and CEA. Br J Cancer. 1994;70:487–92.
Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttila I, Alhava E. Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma. Br J Cancer. 1992;65:731–4.
Ozkan H, Kaya M, Cengiz A. Comparison of tumor marker CA 242 with CA 19–9 and carcinoembryonic antigen (CEA) in pancreatic cancer. Hepatogastroenterology. 2003;50:1669–74.
Strom BL, Maislin G, West SL, et al. Serum CEA and CA 19–9: potential future diagnostic or screening tests for gallbladder cancer? Int J Cancer. 1990;45:821–4.
Del Favero G, Fabris C, Panucci A, Basso D, Plebani M, Baccaglini U, et al. Carbohydrate antigen 19–9 (CA 19–9) and carcinoembryonic antigen (CEA) in pancreatic cancer. Role of age and liver dysfunction. Bull Cancer. 1986;73:251–5.
Engaras B, Hafstrom L, Kewenter J, Nilsson O, Wedel H. Standard serum concentrations and normal fluctuations of CEA, CA 50 and CA 242 during twelve months in men and women aged 60–64 years without malignant disease. Eur J Surg. 1999;165:110–6.
Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the gallbladder. Histologic types, stage of the disease, grade and survival rates. Cancer. 1992;70:1493–7.
Dixon E, Vollmer Jr CM, Sahajpal A, et al. An aggressive surgical approach leads to improved survival in patients with gallbladder cancer: a 12-year study at a North American Center. Ann Surg. 2005;241:385–94.
Batra Y, Pal S, Dutta U, et al. Gallbladder cancer in India: a dismal picture. J Gastroenterol Hepatol. 2005;20:309–14.
Park JS, Oh SY, Kim SH, Kwon HC, Kim JS, Jin-Kim H, et al. Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study. Jpn J Clin Oncol. 2005;35:68–73.
Thongprasert S, Napapan S, Charoentum C, Moonprakan S. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol. 2005;16:279–81.
Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttila I, Alhava E. Receiver operating characteristic (ROC) curve analysis of the tumour markers CEA, CA 50 and CA 242 in pancreatic cancer: results from a prospective study. Br J Cancer. 1993;67:852–5.
Dutta U, Garg PK, Kumar R, Tandon RK. Typhoid carriers among patients with gallstones are at increased risk for carcinoma of the gallbladder. Am J Gastroenterol. 2000;95:784–7.
Kim SB, Fernandes LC, Saad SS, Matos D. Assessment of the value of preoperative serum levels of CA 242 and CEA in the staging and postoperative survival of colorectal adenocarcinoma patients. Int J Biol Markers. 2003;18:182–7.
Dutta U, Nagi B, Garg PK, Sinha SK, Singh K, Tandon RK. Patients with gallstones develop gallbladder cancer at an earlier age. Eur J Cancer Prev. 2005;14:381–5.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rana, S., Dutta, U., Kochhar, R. et al. Evaluation of CA 242 as a Tumor Marker in Gallbladder Cancer. J Gastrointest Canc 43, 267–271 (2012). https://doi.org/10.1007/s12029-011-9288-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12029-011-9288-7